| DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer (NCT03505710) | Daiichi Sankyo | 2018-05-21 |
| Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors (NCT03490669) | AstraZeneca | 2018-05-21 |
| A Prospective Study of Electronic Symptom Reporting Via Mobile Phone Among Patients With Advanced Non-Small Cell Lung Cancer (NCT03616522) | Abramson Cancer Center at Penn Medicine | 2018-05-21 |
| Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer (NCT03520686) | ImmunityBio, Inc. | 2018-05-18 |
| Pilot Study to Investigate The Diagnostic Yield and Utility of 22g and 19g Endobronchial Ultrasound Transbronchial Needle Aspirate (NCT03311620) | Fox Chase Cancer Center | 2018-05-15 |
| Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLC (NCT03527251) | Sun Yat-sen University | 2018-05-15 |
| Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS (NCT03496766) | Spanish Lung Cancer Group | 2018-05-07 |
| A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (NCT03475953) | Institut Bergonié | 2018-05-04 |
| A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF) (NCT03472560) | Pfizer | 2018-05-02 |
| Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer (NCT03461185) | Xinqiao Hospital of Chongqing | 2018-05-01 |
| GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors (NCT03576131) | Genmab | 2018-04-30 |
| CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers (NCT03454451) | Corvus Pharmaceuticals, Inc. | 2018-04-25 |
| Safety, Tolerability and Pharmacokinetics of SH-1028 in Patients With Advanced NSCLC (NCT03603262) | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 2018-04-25 |
| Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) (NCT03425643) | Merck Sharp & Dohme LLC | 2018-04-24 |
| A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors (NCT03518554) | Jacobio Pharmaceuticals Co., Ltd. | 2018-04-23 |
| Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas (NCT03233724) | National Cancer Institute (NCI) | 2018-04-11 |
| Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) (NCT03473925) | Merck Sharp & Dohme LLC | 2018-04-10 |
| Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC (NCT03425331) | Dana-Farber Cancer Institute | 2018-04-10 |
| A Review of Low-Dose CT Lung Cancer Screenings in a Community-Based Healthcare System With High Incidence (NCT03560791) | St Elizabeth Healthcare | 2018-04-06 |
| Patient Activation Through Counseling, Exercise and Mobilization (NCT03411200) | Herlev and Gentofte Hospital | 2018-04-04 |
| LIFE - Lung Cancer, Immunotherapy, Frailty, Effect (NCT03870464) | University of Southern Denmark | 2018-04-01 |
| Texture Features and PDL1 in CT-PET 18 FDG (NCT04309422) | University Hospital, Montpellier | 2018-04-01 |
| Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer (NCT03519971) | AstraZeneca | 2018-03-29 |
| Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKI (NCT04510415) | Hanmi Pharmaceutical Company Limited | 2018-03-29 |
| G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer (NCT03455829) | G1 Therapeutics, Inc. | 2018-03-29 |
| A Real-world Study to Explore Recurrence/Metastases of the NSCLC Patients and the Impact Factors of Patient Survivals (NCT03710616) | The First Affiliated Hospital of Guangzhou Medical University | 2018-03-24 |
| Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC) (NCT03095612) | University of Texas Southwestern Medical Center | 2018-03-22 |
| Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer (NCT03382912) | Eli Lilly and Company | 2018-03-22 |
| Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer (NCT03382899) | Eli Lilly and Company | 2018-03-19 |
| Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A (NCT03447769) | Novartis Pharmaceuticals | 2018-03-16 |
| Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer (NCT03438318) | Regeneron Pharmaceuticals | 2018-03-15 |
| A Study to Investigate the Food Effect on the Pharmacokinetics of Ensartinib Capsules in Chinese Healthy Volunteers. (NCT03510611) | Betta Pharmaceuticals Co., Ltd. | 2018-03-12 |
| CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors (NCT03511391) | University Hospital, Ghent | 2018-03-09 |
| A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer (NCT03048136) | Bristol-Myers Squibb | 2018-03-09 |
| Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC (NCT03371992) | Nilogen Oncosystems | 2018-03-09 |
| Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer (NCT03409614) | Regeneron Pharmaceuticals | 2018-03-06 |
| Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (NCT03228186) | University of Michigan Rogel Cancer Center | 2018-03-05 |
| Clinical Trial of Thoracoscopic Lobecotmy Under Spontaneous Ventilating Anesthesia (NCT03432637) | Guangzhou Institute of Respiratory Disease | 2018-03-05 |
| Effects of Nonintubated Thoracoscopic Lobectomy on Lung Protection (NCT03471884) | National Taiwan University Hospital | 2018-03-01 |
| WHENII - Early Response Evaluation With FDG-PET/CT and Liquid Biopsy in Patients With NSCLC (NCT03481101) | Rigshospitalet, Denmark | 2018-02-28 |
| Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer (NCT03419559) | Iovance Biotherapeutics, Inc. | 2018-02-28 |
| Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer (NCT03460275) | Sun Yat-sen University | 2018-02-26 |
| Pulmonary Physiology and Systemic Inflammatory in EO Pulmonary Events With Brigatinib Use in NSCLC and Other Diseases (NCT03389399) | University of Colorado, Denver | 2018-02-22 |
| Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition (NCT03275597) | University of Wisconsin, Madison | 2018-02-20 |
| Satisfaction and Quality of Life Comparison Between Patients Using Cicaplast Baume B5 Versus Dexeryl for the Management of Cutaneous Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors (iEGFR) (NCT03421912) | Centre Leon Berard | 2018-02-16 |
| 99mTc/68Ga Labeled Anti-PD-L1 sdAb in Assessment of PD-L1 Expression in NSCLC (NCT02978196) | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 2018-02-15 |
| Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer (NCT03232892) | University of California, San Francisco | 2018-02-13 |
| A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (NCT03296163) | mAbxience Research S.L. | 2018-02-06 |
| A Study for Identification of Predictive Immune Biomarker in Peripheral Blood for Nivolumab Therapy in NSCLC Patients (NCT03486119) | Yonsei University | 2018-02-05 |
| Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer (NCT03377023) | H. Lee Moffitt Cancer Center and Research Institute | 2018-02-02 |
| QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors (NCT03169738) | ImmunityBio, Inc. | 2018-02-01 |
| Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC (NCT03525782) | The First Affiliated Hospital of Guangdong Pharmaceutical University | 2018-02-01 |
| First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01) (NCT03401385) | Daiichi Sankyo Co., Ltd. | 2018-01-31 |
| A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer (NCT03392246) | Dana-Farber Cancer Institute | 2018-01-31 |
| Dabrafenib and/or Trametinib Rollover Study (NCT03340506) | Novartis Pharmaceuticals | 2018-01-26 |
| BT1718 in Patients with Advanced Solid Tumours. (NCT03486730) | Cancer Research UK | 2018-01-24 |
| PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer (NCT03774732) | UNICANCER | 2018-01-24 |
| Exhaled Breath Particles in Lung Cancer (NCT05395611) | Lund University Hospital | 2018-01-23 |
| SUNSET: SBRT for Ultra-central NSCLC- a Safety and Efficacy Trial (NCT03306680) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2018-01-19 |
| FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors (NCT03319459) | Fate Therapeutics | 2018-01-18 |
| Clinical Trial for Post-marketing Evaluation of Sheng Bai Oral Liquid (NCT03413358) | BeiJing Yijiayi Medicine Techonoloy Co., Ltd. | 2018-01-15 |
| Detecting Radiation-Induced Cardiac Toxicity After Non-Small Cell Lung Cancer Radiotherapy (NCT03416972) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2018-01-11 |
| NSCLC Heterogeneity in Early Stage Patients and Prediction of Relapse Using a Personalized "Liquid Biopsy" (NCT03771404) | Hellenic Oncology Research Group | 2018-01-05 |
| Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies (NCT03367819) | Sanofi | 2018-01-04 |
| Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions and Differentiating Multiple Primary Lung Cancer From Intrapulmonary Metastases of Non-small Cell Lung Cancer (NCT03679936) | Fifth Affiliated Hospital, Sun Yat-Sen University | 2018-01-03 |
| Local Radiotherapy for Residual Tumor Lesions During the First-line Treatment (NCT05205226) | Hunan Province Tumor Hospital | 2018-01-02 |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry (NCT03452774) | Massive Bio, Inc. | 2018-01-01 |
| Treatment of Non-small Cell Lung Cancer With Cytokine-induced Killer (CIK) Cells Blocked by PD-1 Antibody (NCT03282435) | Dalian University | 2018-01-01 |
| Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer (NCT03647111) | Hunan Province Tumor Hospital | 2018-01-01 |
| Understanding Evidence-Based Practice Patterns in Advanced NSCLC (NCT03107156) | Carevive Systems, Inc. | 2018-01-01 |
| Radiotherapy Combined With Immunotherapy for Brain Metastases of Non-small Cell Lung Cancer (NCT04835025) | Tongji Hospital | 2018-01-01 |
| A Study to Explore Prognoses of NSCLC Patients Complicated With Oligometastases (NCT03427541) | Tang-Du Hospital | 2017-12-31 |
| A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia (NCT03195491) | Bristol-Myers Squibb | 2017-12-25 |
| Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies (NCT03317496) | Pfizer | 2017-12-21 |
| A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors (NCT03289962) | Genentech, Inc. | 2017-12-21 |
| Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (NCT03334617) | AstraZeneca | 2017-12-18 |
| Biomarkers for Risk Stratification in Lung Cancer (NCT03774758) | University of California, San Francisco | 2017-12-17 |
| Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION) (NCT03345810) | AIO-Studien-gGmbH | 2017-12-14 |
| Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer (NCT03237377) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2017-12-12 |
| Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma (NCT03307759) | Peter MacCallum Cancer Centre, Australia | 2017-12-07 |
| A Study to Explore Clinical Characteristics and Prognoses of N2 Patients With Non-small Cell Lung Cancer (NCT03429192) | Tianjin Chest Hospital | 2017-12-01 |
| A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies (NCT03329950) | Celldex Therapeutics | 2017-12-01 |
| A Study to Evaluate Effectiveness and Safety of Surgeries in Elderly NSCLC Patients (NCT03429673) | China-Japan Friendship Hospital | 2017-12-01 |
| A Study to Evaluate Effectiveness of Sublobar Dissection in Patients With Non-small Cell Lung Cancer (NCT03427567) | Tongji Hospital | 2017-12-01 |
| A Study to Explore Prognoses of the Patients With N2 Non-small Cell Lung Cancer (NCT03451526) | Tang-Du Hospital | 2017-12-01 |
| Nab-Paclitaxel Versus Paclitaxel Plus Carboplatin in Advanced Squamous Cell Non Small Cell Lung Cancer (NCT03262948) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2017-12-01 |
| An Observational Study to Explore Clinical Characteristics of the Patients With T1 Non-small Cell Lung Cancer (NCT03413956) | Jiangsu Cancer Institute & Hospital | 2017-12-01 |
| Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC) (NCT03358875) | BeiGene | 2017-11-30 |
| Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer (NCT03087760) | Abramson Cancer Center at Penn Medicine | 2017-11-29 |
| A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer (NCT03533127) | Luye Pharma Group Ltd. | 2017-11-27 |
| T-Cell PET Imaging With [18F]F-AraG in Lung Cancer (NCT03311672) | University of California, San Francisco | 2017-11-26 |
| A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC Patients (NCT03373955) | Sichuan University | 2017-11-23 |
| A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors (NCT03343613) | Eli Lilly and Company | 2017-11-17 |
| Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers (NCT03195699) | Tvardi Therapeutics, Incorporated | 2017-11-15 |
| Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea (NCT03271554) | Hoffmann-La Roche | 2017-11-09 |
| Haploidentical NK Cells After Pemetrexed in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) (NCT03366064) | Asan Medical Center | 2017-11-09 |
| Precision-exercise-prescription for Lung Cancer Patients Undergoing Surgery: The PEP Study (NCT03306992) | University of Utah | 2017-11-07 |
| Outcomes With Immune Checkpoint Inhibitor for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases (NCT05129202) | Hunan Province Tumor Hospital | 2017-11-03 |
| Combination of Platinum Doublets and Hypofractionated Radiotherapy in NSCLC (NCT02947113) | The Netherlands Cancer Institute | 2017-11-01 |
| Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759 (NCT03360929) | LYZZ Alpha Holding Ltd | 2017-10-30 |